CLINDAMYCIN QUALIGEN 150 mg HARD CAPSULES

Introduction

Package Leaflet: Information for the User

Clindamicina Qualigen 150 mg Hard Capsules EFG

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

• Keep this leaflet, you may need to read it again.
• If you have any further questions, ask your doctor or pharmacist.

• This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
• If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the Package Leaflet

1. What is Clindamicina Qualigen and what is it used for
2. What you need to know before you take Clindamicina Qualigen
3. How to take Clindamicina Qualigen
4. Possible side effects
   1. Storage of Clindamicina Qualigen

1. Contents of the pack and further information

1. What is Clindamicina Qualigen and what is it used for

This medicinal product belongs to a group of antibiotics called lincosamides.

Antibiotics are used to treat bacterial infections and are not effective against viral infections such as the flu or the common cold.

It is essential that you follow the instructions regarding dosage, administration, and treatment duration as indicated by your doctor.

Do not store or reuse this medication. If you have any leftover antibiotic after completing the treatment, return it to the pharmacy for proper disposal. Do not throw away medicines via wastewater or household waste.

It is used to treat infections caused by bacteria in different parts of the body, in adults.

Additionally, this medication is used to treat acute sinusitis (infection of the paranasal sinuses) in children over 1 month and under 18 years of age.

2. What you need to know before you take Clindamicina Qualigen

Do not take Clindamicina hard capsules

• If you are allergic to clindamycin, lincomycin, or any of the other ingredients of this medicinal product (listed in section 6).
• If you have previously suffered from antibiotic-associated colitis.

Warnings and precautions

• During treatment, allergic reactions (including anaphylactic reaction and shock) may occur, in which case, treatment with Clindamicina should be discontinued and appropriate treatment initiated.
• During treatment with this medicinal product or after it, symptoms suggesting antibiotic-associated colitis (diarrhea) may appear. If this occurs, treatment should be suspended, and your doctor will prescribe the most suitable treatment.
• If you have an inflammatory bowel disease, such as Crohn's disease or ulcerative colitis, discuss this with your doctor to confirm whether you should use this medicinal product.
• Prolonged administration of this medicinal product may cause the growth of other microorganisms, especially fungi.
• If you are being treated with neuromuscular blockers (used to produce muscle paralysis, such as pancuronium, tubocurarine), inform your doctor, as clindamycin may potentiate the action of these medicinal products.
• If treatment with Clindamicina is prolonged, you should undergo periodic blood tests and examinations to assess blood count and liver and kidney function.
• Acute kidney disorders may occur. Inform your doctor about any medicinal products you are currently taking and if you have any kidney problems. If you experience decreased urine production, fluid retention causing swelling in your legs, ankles, or feet, shortness of breath, or nausea, you should contact your doctor immediately.

Children and adolescents

This medicinal product is not suitable for children who are unable to swallow the capsules whole.

The recommended dose in children over 1 month is 8 to 25 mg/kg/day divided into 3 or 4 equal doses, see section 3 for more information.

Using Clindamicina hard capsules with other medicinal products

Inform your doctor or pharmacist if you are using or have recently used other medicinal products, including those obtained without a prescription.

You should inform your doctor if you are taking any of the following medicinal products:

• Vitamin K antagonist (anticoagulants), as they should prescribe frequent blood coagulation tests.
• Neuromuscular blocking agent (such as pancuronium, tubocurarine), as their effect may be potentiated by the use of this medicinal product.
• Oral typhoid vaccine, as it is inactivated by concomitant administration of antibacterial agents; Clindamicina should not be administered in the 3 days prior to or after vaccination.

Taking Clindamicina hard capsules with food and drinks

The capsules can be taken with food, as food intake does not modify the absorption of Clindamicina. It is recommended to take the capsules with a large glass of water to avoid possible esophageal irritation.

Pregnancy, breastfeeding, and fertility

Pregnancy

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicinal product.

Clindamycin crosses the placental barrier in humans. In clinical studies with pregnant women, systemic administration of clindamycin during the second and third trimesters has not been associated with an increased frequency of congenital anomalies. There are no sufficient and well-controlled studies with pregnant women during the first trimester of pregnancy.

Therefore, clindamycin should not be used during pregnancy unless it is strictly necessary.

Breastfeeding

Clindamycin is excreted in breast milk after oral or intravenous administration. Due to the potential for serious adverse reactions in the breastfed infant, the use of clindamycin is contraindicated during breastfeeding.

Driving and using machines

The influence of this medicinal product on the ability to drive or use machines is negligible or non-existent.

Clindamicina hard capsules contain lactose

If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medicinal product.

3. How to take Clindamicina Qualigen

Follow the instructions for administration of the medicinal product contained in this package leaflet or as indicated by your doctor. In case of doubt, consult your doctor or pharmacist.

This medicinal product is administered orally.

Your doctor will determine the most suitable dose and treatment duration for you, according to your condition and response to treatment.

Adults

The recommended dose in adults is 600 to 1,800 mg per day divided into 2, 3, or 4 equal doses, depending on the severity, location of the infection, and sensitivity of the microorganism. Your doctor will indicate the regimen to follow.

The treatment duration should be determined based on the type of infection and response, and should be as short as possible, generally 7 to 14 days.

The usual dosage in acute pharyngitis and certain pneumonias is 300 mg, 2 times a day for 10 days.

Pelvic inflammatory disease: after intravenous treatment administered by a healthcare professional, 450-600 mg of clindamycin every 6 hours orally for 10-14 days (complete treatment, including intravenous and oral administration).

Pneumonia in patients with HIV infection: 300-450 mg of clindamycin every 6 hours orally for 21 days. Treatment is performed in combination with primaquine (15-30 mg/day orally).

Toxoplasmic encephalitis in patients with HIV infection: 600-1,200 mg of clindamycin every 6 hours intravenously or orally for 2 weeks.

After this period, 300-600 mg every 6 hours orally for 8-10 weeks. Treatment is performed in combination with pyrimethamine (25-75 mg/day orally) and folinic acid (10-20 mg/day) with the highest doses of pyrimethamine.

Use in elderly patients

No dose adjustment is required in elderly patients with normal hepatic and renal function.

Use in patients with renal impairment

No dose adjustment is required in patients with renal impairment.

Use in patients with hepatic impairment

No dose adjustment is required in patients with hepatic impairment.

Use in children

The recommended dose in children over 1 month is 8 to 25 mg/kg/day divided into 3 or 4 equal doses. The capsules should be taken whole, which should be taken into account when administering the medicinal product.

If you take more Clindamicina hard capsules than you should

In case of overdose, you may experience nausea, vomiting, diarrhea, or allergic reactions.

In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service at 91 562 04 20, indicating the medicinal product and the amount ingested.

Information for the healthcare professional

In case of overdose, peritoneal dialysis or hemodialysis is not effective in eliminating the medicinal product. Gastric lavage may be performed. Treatment with activated charcoal and symptomatic treatment is recommended.

In case of an allergic reaction, the usual emergency treatment should be applied, including corticosteroids, adrenaline, and antihistamines.

If you forget to take Clindamicina

In case of a missed dose, use the medicinal product as soon as possible and continue with the treatment as prescribed. However, if the next dose is near, it is better not to take the missed dose and wait for the next one. Do not take a double dose to make up for the missed dose. Continue using Clindamicina as indicated by your doctor.

If you stop taking Clindamicina

If you stop taking Clindamicina before your doctor recommends, your symptoms may worsen or reappear.

If you have any further questions about the use of this product, ask your doctor or pharmacist.

4. Possible side effects

Like all medicinal products, Clindamicina can cause side effects, although not everybody gets them.

Inform your doctor immediately if you experience:

• fluid retention causing swelling in your legs, ankles, or feet, difficulty breathing, or nausea.

The frequency of adverse reactions during clinical trials was:

Common: may affect up to 1 in 10 people

• abdominal pain, diarrhea, pseudomembranous colitis.
• liver function test abnormalities.

Uncommon: may affect up to 1 in 100 people

• nausea, vomiting.
• red rash on the skin with small grains (macules or papules) (maculopapular rash), red, elevated, and itchy skin lesions (urticaria).

Frequency not known (cannot be estimated from the available data)

• vaginal infection.
• decreased white blood cell count (agranulocytosis, leucopenia, neutropenia), decreased platelet count (thrombocytopenia), increased white blood cell count (eosinophilia).
• allergic reaction (anaphylactoid reaction), drug reaction with eosinophilia and systemic symptoms (DRESS syndrome).
• altered sense of taste.
• esophageal ulcer, esophagitis.
• yellowing of the skin and mucous membranes (jaundice).
• severe skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and erythema multiforme.

Reporting of side effects

If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly to the Spanish Medicines and Healthcare Products Agency (AEMPS) at www.notificaram.es.

By reporting side effects, you can help provide more information on the safety of this medicinal product.

5. Storage of Clindamicina Qualigen

Keep this medicinal product out of the sight and reach of children.

Store below 30°C.

Store in the original packaging to protect from light.

Do not use this medicinal product after the expiry date stated on the carton. The expiry date is the last day of the month indicated.

Medicines should not be disposed of via wastewater or household waste. Dispose of the packaging and any unused medicinal product in the pharmacy's SIGRE collection point. If you have any doubts, ask your pharmacist how to dispose of the packaging and any unused medicinal product. This will help protect the environment.

6. Contents of the pack and further information

Composition

The active substance is clindamycin (as hydrochloride). Each capsule contains 150 mg of clindamycin (in the form of hydrochloride).

The other ingredients are: capsule content (lactose monohydrate, corn starch, magnesium stearate, and talc) and capsule ingredients (titanium dioxide (E171), gelatin, and printing ink: shellac, iron oxide black (E172), propylene glycol (E1520), and ammonium hydroxide (E527)).

Appearance of the product and pack contents

White, size 1, hard capsules, printed with "CLIN 150".

Alu/PVC blisters in a cardboard box, containing 24 capsules.

Marketing authorization holder and manufacturer

Marketing authorization holder

Neuraxpharm Spain, S.L.U.

Avda. Barcelona, 69

08970 Sant Joan Despí

Barcelona – Spain

Manufacturer

Holsten Pharma GmbH

Hahnstrasse 31-35,

Frankfurt/Main

Hessen - 60528

Germany

Date of the last revision of this leaflet:July 2021

Detailed and updated information on this medicinal product is available on the website of the Spanish Agency for Medicines and Healthcare Products (AEMPS) http://www.aemps.gob.es/.